NCT04442581View on ClinicalTrials.gov

Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

April 20, 2021

Primary Completion Date

December 13, 2021

Study Completion Date

March 8, 2022

Conditions
Advanced Hepatocellular CarcinomaBCLC Stage B Hepatocellular CarcinomaBCLC Stage C Hepatocellular Carcinoma
Interventions
DRUG

Cabozantinib S-malate

Given PO

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

lead

University of Washington

OTHER